Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Gentian Diagnostics AS's Revenue for the
three
months ended in Mar. 2026 was kr43.9 Mil. Gentian Diagnostics AS's Total Assets for the quarter that ended in Mar. 2026 was kr247.0 Mil. Therefore, Gentian Diagnostics AS's Asset Turnover for the quarter that ended in Mar. 2026 was 0.18.
Asset Turnover is linked to ROE % through Du Pont Formula. Gentian Diagnostics AS's annualizedROE % for the quarter that ended in Mar. 2026 was -41.61%. It is also linked to ROA % through Du Pont Formula. Gentian Diagnostics AS's annualizedROA % for the quarter that ended in Mar. 2026 was -32.86%.
Gentian Diagnostics AS (OSL:GENT) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Gentian Diagnostics AS's annulizedROE % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Gentian Diagnostics AS's annulizedROA % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Gentian Diagnostics AS Asset Turnover Related Terms
Gentian Diagnostics AS Asset Turnover Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:GENT vs ABT, SYK, MDT: Asset Turnover Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Asset Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Gentian Diagnostics AS (OSL:GENT) has a Asset Turnover of 0.18 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's Asset Turnover too high?
Gentian Diagnostics AS's current Asset Turnover is 0.18. Overall, Gentian Diagnostics AS has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Asset Turnover compare to ABT and SYK?
Gentian Diagnostics AS's Asset Turnover of 0.18 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Medical Devices & Instruments company?
A good Asset Turnover depends on the Medical Devices & Instruments industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Asset Turnover is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Possible Value Trap. The stock's GF Value™ is kr61.81, compared to a current price of kr37.00 — trading 40.1% below its estimated fair value. The current Asset Turnover is 0.18. Gentian Diagnostics AS's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Asset Turnover is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr37.00 is trading 40.1% below its estimated GF Value™ of kr61.81.
GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.
Key valuation signals for OSL:GENT:
Asset Turnover: 0.18
GF Value™: kr61.81 vs. price of kr37.00 (40.1% below fair value)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
72GF Score
Get the complete analysis for OSL:GENT
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
